Show simple item record

dc.contributor.authorHoyle, Alex P
dc.contributor.authorAli, Adnan
dc.contributor.authorJames, Nicholas D
dc.contributor.authorCook, Adrian
dc.contributor.authorParker, Christopher C
dc.contributor.authorde Bono, Johann S
dc.contributor.authorAttard, Gerhardt
dc.contributor.authorChowdhury, Simon
dc.contributor.authorCross, William R
dc.contributor.authorDearnaley, David P
dc.contributor.authorBrawley, Christopher D
dc.contributor.authorGilson, Clare
dc.contributor.authorIngleby, Fiona
dc.contributor.authorGillessen, Silke
dc.contributor.authorAebersold, Daniel M
dc.contributor.authorJones, Rob J
dc.contributor.authorMatheson, David
dc.contributor.authorMillman, Robin
dc.contributor.authorMason, Malcolm D
dc.contributor.authorRitchie, Alastair WS
dc.contributor.authorRussell, Martin
dc.contributor.authorDouis, Hassan
dc.contributor.authorParmar, Mahesh KB
dc.contributor.authorSydes, Matthew R
dc.contributor.authorClarke, Noel W
dc.identifier.citationHoyle, A. P. et al. (2019) Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer, European Urology.
dc.description.abstractBackground Abiraterone acetate received licencing for use in only “high-risk” metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a “risk”-related effect was not seen in the STAMPEDE trial. There remains uncertainty as to whether men with LATITUDE “low-risk” M1 disease benefit from androgen deprivation therapy (ADT) combined with abiraterone acetate and prednisolone (AAP). Objective Evaluation of heterogeneity of effect between LATITUDE high- and low-risk M1 prostate cancer patients receiving ADT + AAP in the STAMPEDE trial. Design, setting, and participants A post hoc subgroup analysis of the 2017 STAMPEDE “abiraterone comparison”. Staging scans for M1 patients contemporaneously randomised to ADT or ADT + AAP within the STAMPEDE trial were evaluated centrally and blind to treatment assignment. Stratification was by risk according to the criteria set out in the LATITUDE trial. Exploratory subgroup stratification incorporated the CHAARTED criteria. Outcome measurements and statistical analysis The primary outcome measure was overall survival (OS) and the secondary outcome measure was failure-free survival (FFS). Further exploratory analysis evaluated clinical skeletal-related events, progression-free survival (PFS), and prostate cancer-specific death. Standard Cox-regression and Kaplan-Meier survival estimates were employed for analysis. Results and limitations A total of 901 M1 STAMPEDE patients were evaluated after exclusions. Of the patients, 428 (48%) were identified as having a low risk and 473 (52%) a high risk. Patients receiving ADT + AAP had significantly improved OS (low-risk hazard ratio [HR]: 0.66, 95% confidence interval or CI [0.44–0.98]) and FFS (low-risk HR: 0.24, 95% CI [0.17–0.33]) compared with ADT alone. Heterogeneity of effect was not seen between low- and high-risk groups for OS or FFS. For OS benefit in low risk, the number needed to treat was four times greater than that for high risk. However, this was not observed for the other measured endpoints. Conclusions Men with mHNPC gain treatment benefit from ADT + AAP irrespective of risk stratification for “risk” or “volume”. Patient summary Coadministration of abiraterone acetate and prednisolone with androgen deprivation therapy (ADT) is associated with prolonged overall survival and disease control, compared with ADT alone, in all men with metastatic disease starting hormone therapy for the first time.en
dc.description.sponsorshipThis study was supported by Cancer Research U.K., Medical Research Council, Astellas Pharma, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi Aventis.en
dc.publisherElsevier BVen
dc.subjectprostate canceren
dc.subjecthormone-naïve prostate canceren
dc.subjecthormone-sensitive prostate canceren
dc.subjectsystemic therapyen
dc.subjectandrogen deprivation therapyen
dc.subjectSTAMPEDE trialen
dc.subjectadjuvant treatmenten
dc.titleAbiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate canceren
dc.typeJournal articleen
dc.identifier.journalEuropean Urologyen
rioxxterms.funderCancer Research U.K., Medical Research Council, Astellas Pharma, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi Aventis
dc.description.versionPublished version

Files in this item

Publisher version
euro onc Aug 19.pdf

This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as